Hemophilia A pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 7: Line 7:


==Pathophysiology==
==Pathophysiology==
*The ''F8'' gene associated with the development of Hemophilia A is located close to the tip Xq, and affects production of clotting factor VIII. Abnormalities in the ''F8'' gene cause a relative deficiency in factor VIII, resulting in improper [[hemostasis]] and abnormal or excessive bleeding.<ref> Konkle BA, Josephson NC, Nakaya Fletcher S. Hemophilia A. 2000 Sep 21 [Updated 2014 Jun 5]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: http://www-ncbi-nlm-nih-gov.laneproxy.stanford.edu/books/NBK1404/ </ref>
*The ''F8'' gene associated with the development of Hemophilia A is located close to the tip Xq, and affects production of clotting factor VIII. Abnormalities in the ''F8'' gene cause a relative deficiency in factor VIII, resulting in improper [[hemostasis]] and abnormal or excessive bleeding<ref> Konkle BA, Josephson NC, Nakaya Fletcher S. Hemophilia A. 2000 Sep 21 [Updated 2014 Jun 5]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: http://www-ncbi-nlm-nih-gov.laneproxy.stanford.edu/books/NBK1404/ </ref>
*This trait is inherited in an X-linked recessive manner, affecting males and homozygous females (very rare).
*This trait is inherited in an X-linked recessive manner, affecting males and homozygous females (very rare)
*One-third of new cases of Hemophilia A are due to spontaneous mutations in the [[X chromosome]], not inherited from either parent.
*One-third of new cases of Hemophilia A are due to spontaneous mutations in the [[X chromosome]], not inherited from either parent
*In rare cases, individuals may develop hemophilia later in life. This acquired form of the disease results from development of antibodies to factor VIII.<ref>Handbook of Genetic Counseling/Hemophilia and Von Willebrand Disease – Wikibooks, open books for an open world. Available at https://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Hemophilia_and_Von_Willebrand_Disease Accessed on July 30,2016 </ref><ref name="pmid23696725">{{cite journal| author=Pandey GS, Yanover C, Howard TE, Sauna ZE| title=Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment. | journal=PLoS Comput Biol | year= 2013 | volume= 9 | issue= 5 | pages= e1003066 | pmid=23696725 | doi=10.1371/journal.pcbi.1003066 | pmc=3656107 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23696725  }} </ref>
*In rare cases, individuals may develop hemophilia later in life. This acquired form of the disease results from development of antibodies to factor VIII<ref>Handbook of Genetic Counseling/Hemophilia and Von Willebrand Disease – Wikibooks, open books for an open world. Available at https://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Hemophilia_and_Von_Willebrand_Disease Accessed on July 30,2016 </ref><ref name="pmid23696725">{{cite journal| author=Pandey GS, Yanover C, Howard TE, Sauna ZE| title=Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment. | journal=PLoS Comput Biol | year= 2013 | volume= 9 | issue= 5 | pages= e1003066 | pmid=23696725 | doi=10.1371/journal.pcbi.1003066 | pmc=3656107 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23696725  }} </ref>


==References==
==References==

Revision as of 03:10, 7 May 2017

Hemophilia A Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemophilia A from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemophilia A pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemophilia A pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemophilia A pathophysiology

CDC on Hemophilia A pathophysiology

Hemophilia A pathophysiology in the news

Blogs on Hemophilia A pathophysiology

Directions to Hospitals Treating Hemophilia A

Risk calculators and risk factors for Hemophilia A pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahd Yunus, M.D. [2]

Overview

The pathogenesis of Hemophilia A is characterized by genetic deficiency in Factor VIII.

Pathophysiology

  • The F8 gene associated with the development of Hemophilia A is located close to the tip Xq, and affects production of clotting factor VIII. Abnormalities in the F8 gene cause a relative deficiency in factor VIII, resulting in improper hemostasis and abnormal or excessive bleeding[1]
  • This trait is inherited in an X-linked recessive manner, affecting males and homozygous females (very rare)
  • One-third of new cases of Hemophilia A are due to spontaneous mutations in the X chromosome, not inherited from either parent
  • In rare cases, individuals may develop hemophilia later in life. This acquired form of the disease results from development of antibodies to factor VIII[2][3]

References

  1. Konkle BA, Josephson NC, Nakaya Fletcher S. Hemophilia A. 2000 Sep 21 [Updated 2014 Jun 5]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016. Available from: http://www-ncbi-nlm-nih-gov.laneproxy.stanford.edu/books/NBK1404/
  2. Handbook of Genetic Counseling/Hemophilia and Von Willebrand Disease – Wikibooks, open books for an open world. Available at https://en.wikibooks.org/wiki/Handbook_of_Genetic_Counseling/Hemophilia_and_Von_Willebrand_Disease Accessed on July 30,2016
  3. Pandey GS, Yanover C, Howard TE, Sauna ZE (2013). "Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment". PLoS Comput Biol. 9 (5): e1003066. doi:10.1371/journal.pcbi.1003066. PMC 3656107. PMID 23696725.

Template:WH Template:WS